^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

DNA damage stimulant

Related drugs:
8ms
ARGLU1 enhances promoter-proximal pausing of RNA polymerase II and stimulates DNA damage repair. (PubMed, Nucleic Acids Res)
Significantly, overexpression of ARGLU1 increased cancer cell resistance to genotoxic drugs and promoted DNA damage repair. These results identify new roles for ARGLU1 in cancer cell survival and the DNA damage repair pathway, with potential clinical implications for chemotherapy resistance.
Journal
|
BRD4 (Bromodomain Containing 4)
over2years
Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition. (PubMed, Int J Mol Sci)
Transcriptomic classification of cancer cell lines based on MET expression showed that response to the PARP inhibitor (PARPi) olaparib is poorer in MET overexpressing cell lines...Given the role played by NuMA in mitosis, data show that the latter is affected by MET and PARP inhibition in cells with haploinsufficient ATM. This is important as ATM heterozygous mutation is frequently found in human cancer and in lung carcinomas in particular.
Journal • PARP Biomarker
|
ATM (ATM serine/threonine kinase)
|
ATM mutation • MET overexpression • MET expression • MET-H
|
Lynparza (olaparib)
over2years
Cryptocaryone Promotes ROS-Dependent Antiproliferation and Apoptosis in Ovarian Cancer Cells. (PubMed, Cells)
These CPC-associated principal biological processes were validated to be oxidative stress-dependent by N-acetylcysteine. In conclusion, CPC is a potential anti-OVCA natural product showing oxidative stress-dependent antiproliferation, apoptosis, and DNA damaging functions.
Journal
|
CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • CASP7 (Caspase 7)
over2years
Preclinical evaluation of CAP-0121 for multidrug resistant cancers (AACR 2022)
This response of CAP-0121 in drug resistant xenografts is observed at nontoxic doses. Synergistic action is observed when CAP-0121 is administered in combination with traditional drugs used for treating ovarian cancer, including taxanes, platinum agents, and PARP inhibitors.
Preclinical
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1)
|
CAP-0121 • irofulven-1 (LP-100)
almost3years
Exploring the Mechanism of Baicalin Intervention in Breast Cancer Based on MicroRNA Microarrays and Bioinformatics Strategies. (PubMed, Evid Based Complement Alternat Med)
Baicalin inhibits the proliferation of breast cancer cells. It may achieve antitumor effects through regulating microRNAs so as to affect the DNA replication (such as cellular response to DNA damage stimulus and DNA binding), RNA transcription (such as regulation of transcription, DNA-templated, transcription from RNA polymerase II promoter, and transcription factor binding), protein synthesis (such as mRNA binding, Golgi apparatus, and protein complex), endocytosis, pathways in cancer, p53 signaling pathway, and so on.
Journal
|
MIR100 (MicroRNA 100) • MIR193B (MicroRNA 193b) • Let-7c (MicroRNA Let-7c) • MIR126 (MicroRNA 126) • MIR31 (MicroRNA 31) • MIR504 (MicroRNA 504) • MIR15A (MicroRNA 15a) • MIR181B1 (MicroRNA 181b-1)